カテゴリ： GlobalData, ドイツ, 企業調査

Stada Arzneimittel AG (SAZ)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Stada Arzneimittel AG (SAZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9925
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：81
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of products in various therapeutic categories including pain, women’s health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin, Pantoprazol, Epoetin zeta and Diclofenac. Its major branded products include APO-Go, Grippostad, Snup, Fultium, and Vitaprost. The company operates in more than 30 countries with sales in Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG (SAZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15
STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16
Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17
Nizhpharm Completes Acquisition Of Aqualor Product Portfolio For US$178 Million 18
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 19
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 20
Private Equity 22
Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 22
Ardian May Sell Riemser Pharma for USD494.3 Million 24
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 26
Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 28
Partnerships 30
Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 30
Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 31
Theratechnologies Enters into Commercialization Agreement with BL&H 32
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 33
Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 34
Licensing Agreements 35
BL&H Enters into Licensing Agreement with Race Oncology 35
BL&H Enter into Licensing Agreement with MDNA Life Sciences 36
Thornton & Ross Enters into Licensing Agreement with Futura Medical 37
BL&H Enters into Licensing Agreement with Telesta Therapeutics 38
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 39
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 40
Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 41
Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 42
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 44
Equity Offering 45
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 45
Debt Offering 46
Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 46
Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For US$452 Million 47
Asset Transactions 48
DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 48
Acquisition 49
Nidda Healthcare to Acquire Stake in Stada Arzneimittel 49
Elliott Management May Acquire Stake in Stada Arzneimittel 50
STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 51
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 52
Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For US$339 Million 53
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 55
Stada Arzneimittel AG – Key Competitors 56
Stada Arzneimittel AG – Key Employees 57
Stada Arzneimittel AG – Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Recent Developments 61
Financial Announcements 61
Aug 09, 2018: STADA’s business development in the first six months of 2018 as expected 61
May 03, 2018: STADA with solid business development in the first quarter of 2018 63
Mar 08, 2018: STADA records positive business development in 2017 65
Nov 09, 2017: STADA shows good business development in the third quarter of 2017 and the first nine months 68
Corporate Communications 70
Sep 03, 2018: Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO 70
Apr 16, 2018: Changes in the management team of STADA 71
Feb 01, 2018: Supervisory Board of STADA Arzneimittel appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018 72
Feb 01, 2018: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018 73
Jul 04, 2017: STADA Arzneimittel appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions 74
Apr 24, 2017: Dr. Ralph Grobecker to become Managing Director of STADA’s OTC segment 75
Other Significant Developments 76
Sep 12, 2018: STADA invites the holders of the STADA Bond to participate in the bondholders meeting and to vote in favor of the proposed resolutions 76
Mar 08, 2018: CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology 77
Aug 03, 2017: STADA shows good operational development in first six months of 2017 78
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List of Tables
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Stada Arzneimittel AG, Deals By Therapy Area, 2012 to YTD 2018 10
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15
STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16
Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17
Nizhpharm Completes Acquisition Of Aqualor Product Portfolio For US$178 Million 18
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 19
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 20
Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 22
Ardian May Sell Riemser Pharma for USD494.3 Million 24
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 26
Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 28
Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 30
Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 31
Theratechnologies Enters into Commercialization Agreement with BL&H 32
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 33
Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 34
BL&H Enters into Licensing Agreement with Race Oncology 35
BL&H Enter into Licensing Agreement with MDNA Life Sciences 36
Thornton & Ross Enters into Licensing Agreement with Futura Medical 37
BL&H Enters into Licensing Agreement with Telesta Therapeutics 38
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 39
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 40
Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 41
Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 42
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 44
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 45
Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 46
Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For US$452 Million 47
DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 48
Nidda Healthcare to Acquire Stake in Stada Arzneimittel 49
Elliott Management May Acquire Stake in Stada Arzneimittel 50
STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 51
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 52
Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For US$339 Million 53
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 55
Stada Arzneimittel AG, Key Competitors 56
Stada Arzneimittel AG, Key Employees 57
Stada Arzneimittel AG, Subsidiaries 58

List of Figures
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Stada Arzneimittel AG (SAZ)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Heinzel Holding GmbH：企業の戦略的SWOT分析
    Heinzel Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Petrel Resources Plc (PET)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petrel Resources Plc (Petrel Resources) is an oil and gas company that provides exploration and production of crude oil and natural gas across Iraq. The company provides areas of operations such as Luhais and Subba in Southern Iraq, Tano Basin in Ghana, Porcupine Basin in Ireland, and others …
  • Theratechnologies Inc (TH)：企業の財務・戦略的SWOT分析
    Theratechnologies Inc (TH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Extraction Oil & Gas Inc (XOG)：企業の財務・戦略的SWOT分析
    Extraction Oil & Gas Inc (XOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • The Medicines Company (MDCO)：医療機器：M&Aディール及び事業提携情報
    Summary The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle …
  • Actua Corporation：企業のM&A・事業提携・投資動向
    Actua Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Actua Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Humana Inc.：企業の戦略・SWOT・財務分析
    Humana Inc. - Strategy, SWOT and Corporate Finance Report Summary Humana Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nuclear Decommissioning Authority：企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Mitie Group Plc (MTO)：企業の財務・戦略的SWOT分析
    Mitie Group Plc (MTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Genoptix Inc-製薬・医療分野：企業M&A・提携分析
    Summary Genoptix Inc (Genoptix) is a healthcare services provider that offers diagnostic solutions. The center offers oncology diagnostics and informatics services. It provides biopharma and healthcare laboratory, discovery, drug development, care and cost development; diagnostics, and patient servi …
  • Wentworth Resources Ltd (WRL)：企業の財務・戦略的SWOT分析
    Wentworth Resources Ltd (WRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Avidity Biosciences LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary Avidity Biosciences LLC (Avidity Biosciences), formerly Avidity NanoMedicines LLC is a biotech company that develops antibody oligonucleotide conjugates (AOCs). The company’s proprietary platform technology has enhanced pharmacokinetic and biodistribution properties that improves the deliver …
  • Spitfire Oil Ltd (SRO)：企業の財務・戦略的SWOT分析
    Summary Spitfire Oil Ltd (Spitfire) is an oil and gas company that produces and markets liquid hydrocarbons. The company's liquid hydrocarbons include fuel oil and distillate from the Salmon Gums Lignite Deposit. Its Salmon Gums Lignite deposit is located in Western Australia near Salmon Gums and co …
  • Vermont Electric Cooperative, Inc.：企業の戦略的SWOT分析
    Vermont Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Kimco Realty Corp (KIM)：企業の財務・戦略的SWOT分析
    Kimco Realty Corp (KIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Pierrel Spa (PRL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Pierrel Spa (Pierrel) is a pharmaceutical company that offers contract services to biopharmaceutical and life sciences industries across the world. The company offers services in the areas of contract research, discovery of medicinal product candidates, clinical research and contract manufac …
  • The Cooper Companies Inc (COO)：企業の財務・戦略的SWOT分析
    The Cooper Companies Inc (COO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Nelnet, Inc.：企業の戦略・SWOT・財務情報
    Nelnet, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nelnet, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Prezzo Ltd：企業の戦略・SWOT・財務情報
    Prezzo Ltd - Strategy, SWOT and Corporate Finance Report Summary Prezzo Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • CytoDel Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary CytoDel Inc (CytoDel) is a biopharmaceutical company that utilizes molecular biology tools to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company provides product portfolio such as Ctyo-111, an antidote to botulism; and Cyto-012 a recombinant BoNT derivative, among ot …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆